Physician profile
Kevin Sponseller
NPI 1851709554
$18,601.16
in general payments reported to CMS, 2019-2025
70 companies · $2,629 in 2025
The $2,629 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,358 · 2020: $2,154 · 2021: $2,253 · 2022: $3,203 · 2023: $2,982 · 2024: $3,022 · 2025: $2,629.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,572 · Education: $61.14.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,572.25 |
| Education | $61.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,468.18 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Lilly USA, LLC | $1,457.74 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $1,455.54 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $1,330.06 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,268.24 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Novo Nordisk INC | $1,112.30 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $758.67 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Takeda Pharmaceuticals U.S.A., INC. | $615.01 | 2019-2025 | Trintellix |
| Ironwood Pharmaceuticals, INC | $583.47 | 2019-2024 | Linzess |
| Amgen INC. | $530.39 | 2019-2025 | Repatha, Otezla, Otezla |
| Merck Sharp & Dohme LLC | $510.13 | 2019-2024 | Verquvo, Gardasil 9, Gardasil |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $441.13 | 2019-2025 | Xifaxan, Trulance |
| Bayer Healthcare Pharmaceuticals INC. | $400.58 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $389.78 | 2022-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $346.30 | 2022-2025 | Caplyta |
Show all 70 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Sponseller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.